Maravai LifeSciences (NASDAQ:MRVI) Sees Strong Trading Volume – Time to Buy?

Shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) saw unusually-strong trading volume on Wednesday . Approximately 3,047,907 shares were traded during mid-day trading, an increase of 30% from the previous session’s volume of 2,336,194 shares.The stock last traded at $2.18 and had previously closed at $2.16.

Analyst Ratings Changes

A number of analysts recently issued reports on MRVI shares. Baird R W cut Maravai LifeSciences from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 26th. Morgan Stanley decreased their target price on shares of Maravai LifeSciences from $7.00 to $5.00 and set an “equal weight” rating on the stock in a report on Tuesday, March 25th. Bank of America cut their price target on shares of Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating for the company in a report on Monday, March 3rd. The Goldman Sachs Group lowered Maravai LifeSciences from a “neutral” rating to a “sell” rating and dropped their price objective for the company from $7.00 to $4.25 in a research note on Thursday, December 5th. Finally, Guggenheim started coverage on Maravai LifeSciences in a report on Thursday, December 19th. They issued a “neutral” rating for the company. One research analyst has rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $7.31.

Maravai LifeSciences Price Performance

The firm has a market cap of $554.45 million, a P/E ratio of -1.33 and a beta of -0.08. The business has a 50-day simple moving average of $3.61 and a 200 day simple moving average of $5.48. The company has a debt-to-equity ratio of 0.89, a quick ratio of 9.94 and a current ratio of 10.74.

Insider Activity

In related news, General Counsel Kurt Oreshack sold 25,000 shares of the company’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $5.03, for a total value of $125,750.00. Following the sale, the general counsel now directly owns 167,618 shares of the company’s stock, valued at $843,118.54. This represents a 12.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 0.63% of the company’s stock.

Institutional Trading of Maravai LifeSciences

A number of hedge funds and other institutional investors have recently modified their holdings of the business. SG Americas Securities LLC grew its stake in shares of Maravai LifeSciences by 7.3% in the fourth quarter. SG Americas Securities LLC now owns 33,046 shares of the company’s stock worth $180,000 after acquiring an additional 2,239 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Maravai LifeSciences by 10.5% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 30,076 shares of the company’s stock valued at $164,000 after purchasing an additional 2,851 shares during the period. Performa Ltd US LLC grew its position in Maravai LifeSciences by 614.3% in the 4th quarter. Performa Ltd US LLC now owns 5,000 shares of the company’s stock worth $27,000 after purchasing an additional 4,300 shares during the period. FNY Investment Advisers LLC grew its position in Maravai LifeSciences by 600.0% in the 4th quarter. FNY Investment Advisers LLC now owns 7,000 shares of the company’s stock worth $38,000 after purchasing an additional 6,000 shares during the period. Finally, Orion Portfolio Solutions LLC raised its stake in Maravai LifeSciences by 4.8% during the 3rd quarter. Orion Portfolio Solutions LLC now owns 135,749 shares of the company’s stock valued at $1,128,000 after buying an additional 6,177 shares during the last quarter. 50.25% of the stock is owned by hedge funds and other institutional investors.

Maravai LifeSciences Company Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.